These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31195751)

  • 1. Oestrogen Non-Genomic Signalling is Activated in Tamoxifen-Resistant Breast Cancer.
    Poulard C; Jacquemetton J; Trédan O; Cohen PA; Vendrell J; Ghayad SE; Treilleux I; Marangoni E; Le Romancer M
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31195751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant.
    Jacquemetton J; Kassem L; Poulard C; Dahmani A; De Plater L; Montaudon E; Sourd L; Morisset L; El Botty R; Chateau-Joubert S; Vacher S; Bièche I; Treilleux I; Trédan O; Marangoni E; Le Romancer M
    Breast Cancer Res; 2021 May; 23(1):57. PubMed ID: 34020697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR.
    Lu R; Hu X; Zhou J; Sun J; Zhu AZ; Xu X; Zheng H; Gao X; Wang X; Jin H; Zhu P; Guo L
    Nat Commun; 2016 Jul; 7():12044. PubMed ID: 27375289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STAT1 facilitates oestrogen receptor α transcription and stimulates breast cancer cell proliferation.
    Hou Y; Li X; Li Q; Xu J; Yang H; Xue M; Niu G; Zhuo S; Mu K; Wu G; Li X; Wang H; Zhu J; Zhuang T
    J Cell Mol Med; 2018 Dec; 22(12):6077-6086. PubMed ID: 30334368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards Unravelling the Role of ERα-Targeting miRNAs in the Exosome-Mediated Transferring of the Hormone Resistance.
    Andreeva OE; Sorokin DV; Mikhaevich EI; Bure IV; Shchegolev YY; Nemtsova MV; Gudkova MV; Scherbakov AM; Krasil'nikov MA
    Molecules; 2021 Nov; 26(21):. PubMed ID: 34771077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells.
    Yoshimaru T; Komatsu M; Matsuo T; Chen YA; Murakami Y; Mizuguchi K; Mizohata E; Inoue T; Akiyama M; Yamaguchi R; Imoto S; Miyano S; Miyoshi Y; Sasa M; Nakamura Y; Katagiri T
    Nat Commun; 2013; 4():2443. PubMed ID: 24051437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells.
    Zhuang T; Zhu J; Li Z; Lorent J; Zhao C; Dahlman-Wright K; Strömblad S
    Oncotarget; 2015 Dec; 6(41):43853-68. PubMed ID: 26554417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression.
    Zhang B; Zhang X; Tang B; Zheng P; Zhang Y
    Breast Cancer Res Treat; 2012 Nov; 136(2):399-406. PubMed ID: 23053650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells.
    Yue W; Fan P; Wang J; Li Y; Santen RJ
    J Steroid Biochem Mol Biol; 2007; 106(1-5):102-10. PubMed ID: 17616457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
    Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
    Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
    Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
    Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
    Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
    [No Abstract]   [Full Text] [Related]  

  • 14. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
    Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
    Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of the Hedgehog pathway downregulates estrogen receptor alpha signaling in breast cancer cells.
    Diao Y; Azatyan A; Rahman MF; Zhao C; Zhu J; Dahlman-Wright K; Zaphiropoulos PG
    Oncotarget; 2016 Nov; 7(44):71580-71593. PubMed ID: 27689403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization.
    Wrobel K; Zhao YC; Kulkoyluoglu E; Chen KL; Hieronymi K; Holloway J; Li S; Ray T; Ray PS; Landesman Y; Lipka AE; Smith RL; Madak-Erdogan Z
    Mol Endocrinol; 2016 Oct; 30(10):1029-1045. PubMed ID: 27533791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
    Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
    Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression.
    Zhang X; Zhang B; Liu J; Liu J; Li C; Dong W; Fang S; Li M; Song B; Tang B; Wang Z; Zhang Y
    Sci Rep; 2015 Feb; 5():7835. PubMed ID: 25644501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.
    Busonero C; Leone S; Bianchi F; Acconcia F
    Cell Oncol (Dordr); 2018 Dec; 41(6):677-686. PubMed ID: 30182339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cx43 deficiency confers EMT-mediated tamoxifen resistance to breast cancer via c-Src/PI3K/Akt pathway.
    Wu DP; Zhou Y; Hou LX; Zhu XX; Yi W; Yang SM; Lin TY; Huang JL; Zhang B; Yin XX
    Int J Biol Sci; 2021; 17(10):2380-2398. PubMed ID: 34326682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.